NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.70 +0.03 (+0.82 %)
(As of 05/27/2018 09:18 AM ET)
Previous Close$3.70
Today's Range$3.63 - $3.80
52-Week Range$3.22 - $7.95
Volume268,093 shs
Average Volume378,363 shs
Market Capitalization$111.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNAT
CUSIPN/A
Phone858-376-2600

Debt

Debt-to-Equity Ratio0.57
Current Ratio2.41
Quick Ratio2.41

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.38 million
Price / Sales3.14
Cash FlowN/A
Price / CashN/A
Book Value$0.78 per share
Price / Book4.74

Profitability

EPS (Most Recent Fiscal Year)($0.61)
Net Income$-17,390,000.00
Net Margins-49.30%
Return on Equity-64.30%
Return on Assets-21.67%

Miscellaneous

Employees35
Outstanding Shares30,060,000

Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.17). The biotechnology company had revenue of $9.74 million for the quarter, compared to the consensus estimate of $8.88 million. Conatus Pharmaceuticals had a negative return on equity of 64.30% and a negative net margin of 49.30%. View Conatus Pharmaceuticals' Earnings History.

When is Conatus Pharmaceuticals' next earnings date?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Conatus Pharmaceuticals.

What price target have analysts set for CNAT?

6 brokerages have issued twelve-month price targets for Conatus Pharmaceuticals' stock. Their forecasts range from $4.30 to $20.00. On average, they anticipate Conatus Pharmaceuticals' share price to reach $12.1414 in the next year. View Analyst Ratings for Conatus Pharmaceuticals.

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,596,203 shares, an increase of 55.3% from the April 13th total of 1,672,035 shares. Based on an average trading volume of 647,431 shares, the days-to-cover ratio is presently 4.0 days. Currently, 10.5% of the company's stock are sold short.

Who are some of Conatus Pharmaceuticals' key competitors?

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:
  • Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 66)
  • Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 50)
  • Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 63)
  • Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 60)
  • Mr. Daniel L. Ripley, Sr. VP of Bus. Devel., Program & Alliance Management (Age 57)

Has Conatus Pharmaceuticals been receiving favorable news coverage?

Media headlines about CNAT stock have trended somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.16 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Conatus Pharmaceuticals' major shareholders?

Conatus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MPM Asset Management LLC (8.20%), BlackRock Inc. (7.71%), Millennium Management LLC (1.19%), American Century Companies Inc. (0.36%), Alambic Investment Management L.P. (0.29%) and JPMorgan Chase & Co. (0.25%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

Which major investors are selling Conatus Pharmaceuticals stock?

CNAT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Alambic Investment Management L.P.. View Insider Buying and Selling for Conatus Pharmaceuticals.

Which major investors are buying Conatus Pharmaceuticals stock?

CNAT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., MPM Asset Management LLC, American Century Companies Inc., JPMorgan Chase & Co., Wells Fargo & Company MN and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Conatus Pharmaceuticals.

How do I buy shares of Conatus Pharmaceuticals?

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $3.70.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $111.23 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]


MarketBeat Community Rating for Conatus Pharmaceuticals (CNAT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Conatus Pharmaceuticals (NASDAQ:CNAT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Conatus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $12.1414, suggesting that the stock has a possible upside of 228.15%. The high price target for CNAT is $20.00 and the low price target for CNAT is $4.30. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.1414$11.9988$13.67$16.00
Price Target Upside: 228.15% upside171.46% upside160.88% upside248.58% upside

Conatus Pharmaceuticals (NASDAQ:CNAT) Consensus Price Target History

Price Target History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals (NASDAQ:CNAT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018OppenheimerSet Price TargetBuy$14.00HighView Rating Details
4/5/2018SunTrust BanksLower Price TargetBuy$4.30HighView Rating Details
4/5/2018HC WainwrightLower Price TargetBuy ➝ Buy$17.00 ➝ $15.00HighView Rating Details
2/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$20.00HighView Rating Details
1/24/2018S&P Equity ResearchBoost Price Target$5.02 ➝ $5.69HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$16.00N/AView Rating Details
8/3/2017Stifel NicolausReiterated RatingBuy$10.00HighView Rating Details
5/15/2017AegisReiterated RatingBuy$11.00N/AView Rating Details
3/15/2017FBR & CoReiterated RatingOutperform$16.00HighView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Conatus Pharmaceuticals (NASDAQ:CNAT) Earnings History and Estimates Chart

Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals (NASDAQ:CNAT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.87)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.22)($0.19)($0.21)
Q2 20183($0.35)($0.19)($0.25)
Q3 20183($0.24)($0.07)($0.13)
Q4 20182($0.33)($0.23)($0.28)

Conatus Pharmaceuticals (NASDAQ CNAT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.20)N/AView Earnings Details
5/2/2018Q1 2018($0.17)($0.17)$8.88 million$9.74 millionViewListenView Earnings Details
3/7/2018Q4 2017($0.17)($0.15)$9.60 million$8.80 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.05)($0.13)$16.06 million$9.57 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.17)($0.19)$9.33 million$10.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.14)$5.88 million$7.00 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.32)($0.35)$0.80 millionViewN/AView Earnings Details
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.35)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.43)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.39)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.34)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
9/9/2013Q2 2013($0.22)$0.16ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Conatus Pharmaceuticals (NASDAQ:CNAT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Conatus Pharmaceuticals (NASDAQ CNAT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 40.56%
Insider Trading History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals (NASDAQ CNAT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Conatus Pharmaceuticals (NASDAQ CNAT) News Headlines

Source:
DateHeadline
Conatus Pharmaceuticals Inc (CNAT) Expected to Post Quarterly Sales of $9.06 MillionConatus Pharmaceuticals Inc (CNAT) Expected to Post Quarterly Sales of $9.06 Million
www.americanbankingnews.com - May 27 at 2:30 AM
Zacks: Analysts Anticipate Conatus Pharmaceuticals (CNAT) to Announce -$0.20 EPSZacks: Analysts Anticipate Conatus Pharmaceuticals (CNAT) to Announce -$0.20 EPS
www.americanbankingnews.com - May 25 at 5:34 PM
Novartis In Liver Diseases NASH And PBC: A Look At The Bright SideNovartis In Liver Diseases NASH And PBC: A Look At The Bright Side
seekingalpha.com - May 17 at 4:39 PM
Conatus Pharmaceuticals (CNAT) Receives Average Recommendation of "Buy" from AnalystsConatus Pharmaceuticals (CNAT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 10:29 AM
Conatus Pharmaceuticals (CNAT) Short Interest Up 55.3% in AprilConatus Pharmaceuticals (CNAT) Short Interest Up 55.3% in April
www.americanbankingnews.com - May 13 at 1:41 AM
$9.06 Million in Sales Expected for Conatus Pharmaceuticals (CNAT) This Quarter$9.06 Million in Sales Expected for Conatus Pharmaceuticals (CNAT) This Quarter
www.americanbankingnews.com - May 10 at 4:18 AM
Conatus Pharmaceuticals (CNAT) Expected to Announce Earnings of -$0.20 Per ShareConatus Pharmaceuticals (CNAT) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - May 8 at 12:51 PM
Conatus Pharmaceuticals (CNAT) Forecasted to Post Q2 2018 Earnings of ($0.21) Per ShareConatus Pharmaceuticals (CNAT) Forecasted to Post Q2 2018 Earnings of ($0.21) Per Share
www.americanbankingnews.com - May 7 at 2:31 AM
Oppenheimer Brokers Decrease Earnings Estimates for Conatus Pharmaceuticals (CNAT)Oppenheimer Brokers Decrease Earnings Estimates for Conatus Pharmaceuticals (CNAT)
www.americanbankingnews.com - May 7 at 2:31 AM
Oppenheimer Analysts Reduce Earnings Estimates for Conatus Pharmaceuticals (CNAT)Oppenheimer Analysts Reduce Earnings Estimates for Conatus Pharmaceuticals (CNAT)
www.americanbankingnews.com - May 4 at 10:38 AM
Conatus Pharmaceuticals (CNAT) Lifted to "Sell" at ValuEngineConatus Pharmaceuticals (CNAT) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - May 3 at 10:54 PM
BRIEF-Conatus Pharmaceuticals Q1 Revenue $9.7 MillionBRIEF-Conatus Pharmaceuticals Q1 Revenue $9.7 Million
www.reuters.com - May 3 at 4:40 PM
Conatus (CNAT) Q1 Loss In Line, Revenues Beat EstimatesConatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
www.nasdaq.com - May 3 at 4:40 PM
Conatus' (CNAT) Q1 Loss In Line, Revenues Beat EstimatesConatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
finance.yahoo.com - May 3 at 4:40 PM
Conatus Pharmaceuticals (CNAT) PT Set at $14.00 by OppenheimerConatus Pharmaceuticals (CNAT) PT Set at $14.00 by Oppenheimer
www.americanbankingnews.com - May 3 at 12:52 PM
Conatus Pharmaceuticals (CNAT) CEO Steve Mento on Q1 2018 Results - Earnings Call TranscriptConatus Pharmaceuticals' (CNAT) CEO Steve Mento on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:08 AM
Conatus: 1Q Earnings SnapshotConatus: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:08 AM
Conatus Pharmaceuticals (CNAT) Issues  Earnings Results, Meets EstimatesConatus Pharmaceuticals (CNAT) Issues Earnings Results, Meets Estimates
www.americanbankingnews.com - May 2 at 9:44 PM
Conatus Pharmaceuticals EPS in-line, beats on revenueConatus Pharmaceuticals EPS in-line, beats on revenue
seekingalpha.com - May 2 at 4:42 PM
Conatus completes enrollment in mid-stage study of emricasan in NASH cirrhosis; shares ahead 1%Conatus completes enrollment in mid-stage study of emricasan in NASH cirrhosis; shares ahead 1%
seekingalpha.com - April 30 at 4:43 PM
Analysts’ Ratings for Amicus and Its Peers in AprilAnalysts’ Ratings for Amicus and Its Peers in April
finance.yahoo.com - April 30 at 4:43 PM
Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal HypertensionConatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension
finance.yahoo.com - April 30 at 10:18 AM
Conatus Pharmaceuticals: Down But Certainly Not OutConatus Pharmaceuticals: Down But Certainly Not Out
seekingalpha.com - April 28 at 9:38 AM
Short Interest in Conatus Pharmaceuticals (CNAT) Rises By 57.0%Short Interest in Conatus Pharmaceuticals (CNAT) Rises By 57.0%
www.americanbankingnews.com - April 28 at 2:28 AM
Whats in the Cards for Conatus (CNAT) This Earnings Season?What's in the Cards for Conatus (CNAT) This Earnings Season?
www.msn.com - April 27 at 4:36 PM
What's in the Cards for Conatus (CNAT) This Earnings Season?What's in the Cards for Conatus (CNAT) This Earnings Season?
finance.yahoo.com - April 27 at 4:36 PM
Conatus Pharmaceuticals to Report First Quarter 2018 Financial ResultsConatus Pharmaceuticals to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 25 at 4:41 PM
Conatus Pharmaceuticals (CNAT) to Release Quarterly Earnings on WednesdayConatus Pharmaceuticals (CNAT) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:26 AM
Zacks: Analysts Anticipate Conatus Pharmaceuticals (CNAT) Will Post Quarterly Sales of $8.88 MillionZacks: Analysts Anticipate Conatus Pharmaceuticals (CNAT) Will Post Quarterly Sales of $8.88 Million
www.americanbankingnews.com - April 23 at 4:32 AM
 Analysts Anticipate Conatus Pharmaceuticals (CNAT) Will Announce Earnings of -$0.17 Per Share Analysts Anticipate Conatus Pharmaceuticals (CNAT) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 21 at 7:54 AM
Conatus Pharmaceuticals (CNAT) Receives Consensus Rating of "Buy" from AnalystsConatus Pharmaceuticals (CNAT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 19 at 10:41 AM
Conatus Pharmaceuticals (CNAT) Highlights Publication of Results from both In-Vitro & In-Vivo Studies of IDN-7314 Pan-caspase InhibitorConatus Pharmaceuticals (CNAT) Highlights Publication of Results from both In-Vitro & In-Vivo Studies of IDN-7314 Pan-caspase Inhibitor
www.streetinsider.com - April 19 at 9:32 AM
ValuEngine Downgrades Conatus Pharmaceuticals (CNAT) to Strong SellValuEngine Downgrades Conatus Pharmaceuticals (CNAT) to Strong Sell
www.americanbankingnews.com - April 18 at 1:56 PM
Conatus Pharmas IDN-7314 shows encouraging action in preclinical studies; shares up 4% premarketConatus Pharma's IDN-7314 shows encouraging action in preclinical studies; shares up 4% premarket
seekingalpha.com - April 18 at 9:36 AM
Stifel Nicolaus Reaffirms Buy Rating for Conatus Pharmaceuticals (CNAT)Stifel Nicolaus Reaffirms Buy Rating for Conatus Pharmaceuticals (CNAT)
www.americanbankingnews.com - April 13 at 9:26 PM
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with NovartisBiotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
www.zacks.com - April 11 at 9:52 AM
Conatus Pharmaceuticals (CNAT) Raised to Hold at Zacks Investment ResearchConatus Pharmaceuticals (CNAT) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 2:51 PM
Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual MeetingConatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
feeds.benzinga.com - April 9 at 7:49 AM
Q2 2018 EPS Estimates for Conatus Pharmaceuticals Cut by SunTrust Banks (CNAT)Q2 2018 EPS Estimates for Conatus Pharmaceuticals Cut by SunTrust Banks (CNAT)
www.americanbankingnews.com - April 9 at 1:39 AM
Are Options Traders Betting On A Big Move In Conatus Stock?Are Options Traders Betting On A Big Move In Conatus Stock?
www.benzinga.com - April 6 at 4:45 PM
Conatus: Whats Next For This Small-Cap Potential NASH Play?Conatus: What's Next For This Small-Cap Potential NASH Play?
seekingalpha.com - April 6 at 4:45 PM
Analysts’ Ratings For Acorda Therapeutics in April 2018Analysts’ Ratings For Acorda Therapeutics in April 2018
finance.yahoo.com - April 6 at 4:45 PM
Conatus Pharmaceuticals (CNAT) Stock Rating Lowered by ValuEngineConatus Pharmaceuticals (CNAT) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM
Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock?Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock?
www.msn.com - April 6 at 9:31 AM
FY2021 EPS Estimates for Conatus Pharmaceuticals (CNAT) Cut by AnalystFY2021 EPS Estimates for Conatus Pharmaceuticals (CNAT) Cut by Analyst
www.americanbankingnews.com - April 6 at 8:23 AM
Conatus Pharmaceuticals (CNAT) Expected to Announce Quarterly Sales of $8.88 MillionConatus Pharmaceuticals (CNAT) Expected to Announce Quarterly Sales of $8.88 Million
www.americanbankingnews.com - April 6 at 3:58 AM
Conatus' Emricasan Fails in Phase II Study, Shares SinkConatus' Emricasan Fails in Phase II Study, Shares Sink
finance.yahoo.com - April 5 at 4:39 PM
Conatus Pharmaceuticals (CNAT) PT Lowered to $4.30Conatus Pharmaceuticals (CNAT) PT Lowered to $4.30
www.americanbankingnews.com - April 5 at 1:49 PM
Conatus Pharmaceuticals (CNAT) Given a $14.00 Price Target by Oppenheimer AnalystsConatus Pharmaceuticals (CNAT) Given a $14.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 5 at 12:02 PM
Conatus Pharmaceuticals (CNAT) Stock Rating Reaffirmed by HC WainwrightConatus Pharmaceuticals (CNAT) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 5 at 11:27 AM

SEC Filings

Conatus Pharmaceuticals (NASDAQ:CNAT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Conatus Pharmaceuticals (NASDAQ:CNAT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Conatus Pharmaceuticals (NASDAQ CNAT) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.